- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00619125
Proposal Evaluating Time-specific Relationships Between Variables of Pain, Stress, and Bloating in IBS Diarrhea and Constipation Symptoms Using a Palm Pilot
A Proposal to Evaluate Time-specific Relationships Between Variables of Pain, Stress, and Bloating in the Onset of IBS Diarrhea and Constipation Symptoms Using Ecological Momentary Assessment (EMA)
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
80 male and female subjects will be recruited: 20 with IBS D; 20 with IBS C; 20 with IBS M; 20 control (no bowel symptoms).
We will target patients who have maintained a diagnosis of IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C, IBS with Mixed Stool pattern (IBS-M), using Rome III Criteria as well as control subjects without bowel symptoms. Subject participation will be limited to patients who maintain mild or moderate symptom severity score on the functional bowel disorders severity index (FBDSI.) providing they have at least 3 symptom episodes of pain or discomfort in a given week, to assure adequate data collection.
Description
Inclusion Criteria:
- The subject signs and dates a written informed consent form (ICF) prior to any study-related activities, including discontinuation of any prohibited medications.
- The subject has been diagnosed with either IBS-C, IBS-D, IBS-M, or has no history of gastrointestinal symptoms (control group).
- The subject has at least 3 pain episodes a week and does not have constant, unremitting abdominal pain.
- The subject is at least 18 years of age and less than 75 years of age at the time of the screening visit.
- The subject is fluent in English.
- The subject is an ambulatory outpatient. Ambulatory is defined as not depending exclusively on a wheelchair for mobility. Nursing home subjects may be enrolled provided they are ambulatory. Subjects with spinal cord injuries resulting in paraplegia may not be enrolled.
Exclusion Criteria:
The subject exhibits evidence of a biochemical or structural abnormality of the digestive tract. These conditions include (but are not limited to) the following:
- Inflammatory bowel disease (Crohn's disease or ulcerative colitis),
- GI surgery (with the exceptions of appendectomy; cholecystectomy; benign polypectomy; fundoplication without gas bloat syndrome, 6 months post-surgery; herniorrhaphy without bowel resection, 1 month post-surgery; hemorrhoidectomy, at least 2 months post-surgery; and hiatal hernia repair),
- GI malignancy, GI obstruction
- In the opinion of the investigator the subject has a concurrent illness or disability (excluding IBS) that may affect the interpretation of clinical efficacy and/or safety data or otherwise contraindicates participation in this clinical study (e.g., an unstable cardiovascular, renal, hepatic, pulmonary, endocrine, metabolic, GI, hematological, or neurological condition).
- The subject has been diagnosed with a major psychiatric disorder within the past 2 years that required hospitalization and/or involved an attempted suicide (e.g., major depression or psychoses). Subjects diagnosed with a major psychiatric disorder that did not require hospitalization or involve an attempted suicide must have remained on a stable dose of medication for at least 6 months prior to the screening visit.
- The subject has a history of alcohol or substance abuse within the past 2 years.
- The subject has any evidence or treatment of malignancy (other than localized basal cell, squamous cell skin cancer or cancer in situ that has been resected) within the previous 5 years.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
A
20 patients with IBS C
|
Short interval assessment (provided by data from palm pilot) may provide a more accurate picture of patient symptom experience.
|
D
20 Subjects without IBS
|
|
B
20 patients with IBS D
|
Short interval assessment (provided by data from palm pilot) may provide a more accurate picture of patient symptom experience.
|
C
20 patients with IBS M
|
Short interval assessment (provided by data from palm pilot) may provide a more accurate picture of patient symptom experience.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine relation of pain and bloating relative to average pain and bloating scores
Time Frame: 2 weeks
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
determine the association of acute stress with increased pain and bloating scores or with defecation in IBS
Time Frame: 2 weeks
|
2 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Douglas Drossman, MD, UNC-Chapel Hill
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 07-1782
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on IBS, Diarrhea Predominant
-
Mayo ClinicCompletedIBS | Diarrhoea Predominant Irritable Bowel SyndromeUnited States
-
Nutrabiotix, LLCRush University Medical CenterTerminatedConstipation-predominant IBS (IBS-C)United States
-
Xiyuan Hospital of China Academy of Chinese Medical...RecruitingDiarrhea-predominant Irritable Boewl SyndromeChina
-
Tel-Aviv Sourasky Medical CenterCompleted
-
Beth Israel Deaconess Medical CenterTerminated
-
Chengdu University of Traditional Chinese MedicineGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedDiarrhea-predominant Irritable Bowel Syndrome | Functional DiarrheaChina
-
Astellas Pharma IncCompletedDiarrhea-predominant Irritable Bowel SyndromeJapan
-
NovartisCompletedIBS-C and IBS With Mixed Bowel Habits
-
A-Mansia Biotech S.A.Vedic Lifesciences Pvt. Ltd.Not yet recruitingDiarrhea-Predominant Irritable Bowel SyndromeIndia
-
Boston PharmaceuticalsCompletedDiarrhea-predominant Irritable Bowel SyndromeUnited States